Nuvalent, Inc. (NUVL)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Nuvalent, Inc. (NUVL) Discusses Topline Pivotal Data From ALKOVE-1 Trial of Neladalkib in ALK-Positive Non-Small Cell Lung Cancer Transcript
Nuvalent, Inc. ( NUVL ) Discusses Topline Pivotal Data From ALKOVE-1 Trial of Neladalkib in ALK-Positive Non-Small Cell Lung Cancer November 17, 2025 8:00 AM EST Company Participants Chelcie Lister James Porter - CEO, President & Director Christopher Turner - Chief Medical Officer Alexandra Balcom - CFO & Treasurer Darlene Noci - Chief Development Officer Conference Call Participants Bradley Canino - Guggenheim Securities, LLC, Research Division Marc Frahm - TD Cowen, Research Division Laura Prendergast - Stifel, Nicolaus & Company, Incorporated, Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Andrew Berens - Leerink Partners LLC, Research Division Yue-Wen Zhu - LifeSci Capital, LLC, Research Division Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Jin Law - Goldman Sachs Group, Inc., Research Division Kelsey Goodwin - Piper Sandler & Co., Research Division Samuel Alexander Leach - Raymond James & Associates, Inc., Research Division Etzer Darout - Barclays Bank PLC, Research Division Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Xiaochuan Dai - UBS Investment Bank, Research Division Colleen Hanley - Robert W.
Nuvalent: Interesting Product, But Aggressive Valuation
NUVL is approaching the precipice of a first targeted therapy approval in lung cancer. They also have an increasingly deep pipeline of therapies, with an audacious phase 3 trial spinning up in ALK-positive NSCLC. Cash position remains strong as well, but the market is pricing in too much success for me to be comfortable at this time.
Nuvalent, Inc. (NUVL) Presents at UBS Virtual Oncology Day Transcript
Nuvalent, Inc. (NASDAQ:NUVL ) UBS Virtual Oncology Day October 1, 2025 3:30 PM EDT Company Participants James Porter - CEO, President & Director Alexandra Balcom - CFO & Treasurer Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Operator Welcome to the UBS Virtual Event. David Dai, you may begin.
Nuvalent, Inc. (NUVL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Nuvalent, Inc. ever had a stock split?
Nuvalent, Inc. Profile
| Biotechnology Industry | Healthcare Sector | James R. Porter CEO | NASDAQ (NGS) Exchange | 670703107 CUSIP |
| US Country | 162 Employees | - Last Dividend | - Last Split | 29 Jul 2021 IPO Date |
Overview
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on the innovative development of targeted therapies for patients battling cancer. Established in 2017 and based in Cambridge, Massachusetts, the company is at the forefront of addressing some of the most critical challenges in cancer treatment. Through its dedication to science and patient care, Nuvalent is working on pioneering solutions for overcoming treatment resistance, managing central nervous system (CNS)-related adverse effects, and tackling the issue of brain metastases in cancer patients. Their research and development pipeline are primarily concentrated on creating highly selective inhibitors designed to improve the safety and efficacy profiles of existing treatments, thereby potentially extending both the quality and duration of life for patients with specific cancer types.
Products and Services
Nuvalent has a robust portfolio of product candidates, each targeting critical needs in oncology, particularly for lung cancer and other malignancies with specific genetic profiles. These include:
- NVL-520: This novel ROS1-selective inhibitor is engineered to overcome emergent treatment resistance, reduce CNS-related side effects, and address brain metastases in patients with ROS1-positive non-small cell lung cancer (NSCLC). It aims to provide a more effective treatment option where current ROS1 tyrosine kinase inhibitors (TKIs) fall short. NVL-520 is currently undergoing the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial.
- NVL-655: A brain-penetrant ALK-selective inhibitor, NVL-655 targets emergent treatment resistance and aims to reduce CNS-related adverse events and effectively manage brain metastases. This inhibitor is designed to offer an improved treatment alternative for patients encountering limitations with first-, second-, and third-generation ALK inhibitors. It is presently under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial.
- NVL-330: This product candidate is a human epidermal growth factor receptor 2 (HER2)-selective inhibitor focused on treating tumors driven by HER2ex20 mutations, managing brain metastases, and minimizing treatment-limiting adverse events, including the off-target inhibition of wild-type EGFR. NVL-330, notably brain-penetrant, is expected to enter phase 1 trials, demonstrating the company's commitment to advancing care for HER2-positive cancer patients.
Contact Information
